✦ LIBER ✦

Pharmacokinetics of oxytetracycline administered intravenously to 4 to 5 - day-old foals

✍ Scribed by M.G. PAPICH; A.K. WRIGHT; L. PETRIE; G.O. KORSRUD

Book ID: 114744985
Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 375 KB
Volume: 18
Category: Article
ISSN: 0140-7783
DOI: 10.1111/j.1365-2885.1995.tb00607.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of route of administration and ag

Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5-day-old foals

✍ Dr M RENÉE GOLENZ; Dr W. D. WILSON; G. P. CARLSON; THERESE J. CRAYCHEE; JUDITH E 📂 Article 📅 1994 🏛 Equine Veterinary Profession 🌐 English ⚖ 900 KB

The dose-dependent pharmacokinetic profi

The dose-dependent pharmacokinetic profile of 2,4,5-trichlorophenoxy acetic acid following intravenous administration to rats

✍ M.W. Sauerhoff; W.H. Braun; G.E. Blau; P.J. Gehring 📂 Article 📅 1976 🏛 Elsevier Science 🌐 English ⚖ 699 KB

A phase II study of topotecan administer

A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma

✍ Kudelka, A.; Edwards, C.; Freedman, R.; Wallin, B.; Hord, M.; Howell, E.; Harper 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Safety and Efficacy of Intravenous Recom

Safety and Efficacy of Intravenous Recombinant Tissue Plasminogen Activator Administered in the 3- to 4.5-hour Window in Korea

✍ Park, Tai Hwan; Lee, Ji Sung; Park, Sang-Soon; Ko, Youngchai; Lee, Soo Joo; Lee, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 535 KB

A Phase II study of intravenous exatecan

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi

212 POSTER A Phase I study of huC242-DM4

212 POSTER A Phase I study of huC242-DM4 to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors

✍ A.W. Tolcher; A. Ricart; J. Rodon; A. Patnaik; A. Mita; M. Mita; S. Sarantopolus 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 66 KB